Celgene/Zoetis Helminthic Drug Patent Published by EPO
Summary
The European Patent Office published patent application EP4232449A1 for Celgene Corporation and Zoetis LLC, covering heterocyclic compounds and their use for treating helminthic infections and diseases, published April 15, 2026. The compounds carry multiple IPC classifications including C07D 417/14, C07D 413/14, C07D 401/14, C07D 471/04, C07D 491/048, and are designated across 31 European states including DE, FR, GB, IT, NL, ES, PL, SE. The publication establishes priority rights and enables public inspection of the specific heterocyclic compound compositions and therapeutic uses disclosed in the application.
“HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES”
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
The European Patent Office published patent application EP4232449A1 for Celgene Corporation and Zoetis LLC, covering heterocyclic compounds and their use for treating helminthic infections and diseases, published April 15, 2026. The compounds carry multiple IPC classifications including C07D 417/14, C07D 413/14, C07D 401/14, C07D 471/04, C07D 491/048, and are designated across 31 European states including DE, FR, GB, IT, NL, ES, PL, SE.
This published application establishes priority rights and prevents third parties from filing conflicting patent applications in EPO-designated states for the disclosed heterocyclic compound compositions and their use in treating helminthic infections and diseases. Competitors developing similar antiparasitic compounds should review the published claims to assess potential freedom-to-operate implications in European markets.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES
Publication EP4232449A1 Kind: A1 Apr 15, 2026
Applicants
Celgene Corporation, Zoetis LLC
Inventors
HAWRYLUK, Natalie, CANAN, Stacie, CONDROSKI, Kevin, R., BEDORE, Matthew, KYNE, Graham, MENON, Sanjay
IPC Classifications
C07D 417/14 20060101AFI20220429BHEP C07D 413/14 20060101ALI20220429BHEP C07D 401/14 20060101ALI20220429BHEP C07D 471/04 20060101ALI20220429BHEP C07D 491/048 20060101ALI20220429BHEP A61P 33/10 20060101ALI20220429BHEP A61K 31/4402 20060101ALI20220429BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.